The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data:
News
in Numbers

71  

The average number of cyber attacks per pharmaceutical drug manufacturing company over a three-month period, according to a new report by ProofPoint.

$43m 

Atai has raised $43m in second-round financing to repurpose compounds in illicit drugs to advance new medicines for mental illnesses

€460m  

The estimated value of pharmaceutical exports likely to be affected by measures implemented by Turkey according to a dispute filed in the WHO by the EU

Three

Exscientia has announced a three-year AI drug discovery collaboration with Celgene

News

90

Under new rules India’s CDSCO will now have 90 days to decide whether to approve global clinical-trial applications and 30 days for domestic trials

Data:
News
in Numbers

71  

The average number of cyber attacks per pharmaceutical drug manufacturing company over a three-month period, according to a new report by ProofPoint.

$43m

Atai has raised $43m in second-round financing to repurpose compounds in illicit drugs to advance new medicines for mental illnesses

90 

Under new rules India’s CDSCO will now have 90 days to decide whether to approve global clinical-trial applications and 30 days for domestic trials

€460m 

The estimated value of pharmaceutical exports likely to be affected by measures implemented by Turkey according to a dispute filed in the WHO by the EU

Three 

Exscientia has announced a three-year AI drug discovery collaboration with Celgene

Biotech growth in UK booms 65% since 2016

New analysis by investment manager Downing LLP has shown that the number of active UK biotechnology businesses in the field of research and experimental development has soared by 65% in just over three years.

Source: The Pharma Times

 New report seeks to improve vaccine programs through effective data use

A new report from the Pan American Health Organization and PATH, ‘Immunization Data: Evidence for Action’, has launched to provide the immunization community with clear, proven strategies for improving the quality and use of immunization data.

Source: PAHO

 Lyrica reclassified after being linked to 33 deaths

On the back of a public consultation and advice from the Advisory Council on the Misuse of Drugs, the Pfizer's Lyrica (pregabalin) will be reclassified as a class C controlled substance from April.

The medication is used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalised anxiety disorder, but can become severely addictive and has been linked to as many as 33 deaths in Northern Ireland just last year.

Source: The Pharma Times

 Novo invests $100M to ready plant for new-generation insulins

Novo Nordisk has reached an agreement that will hold off generic competition to its newer diabetes drugs for another five years. This means that the company can now focus on developing next-generation products and so the drugmaker said it will spend DKK650m ($97.8m) to upgrade and expand facilities at its production site in Kalundborg, Denmark.

Source: FIERCE PHARMA

 Big Pharma come together for better drug side effect detection

An international group of some of the world’s largest pharmaceutical companies has convened to improve the detection of drug side effects.

The Drug Safety Research Unit (DSRU) established the international group that consists of pharma giants such as Pfizer, Roche, BMS, Takeda, Lilly, Gilead, Alexion and Celgene to explore better ways of identifying adverse side effects from licensed medicines.

Source: Pharma Times

Approvals

Cosentyx

Novartis’ psoriasis blockbuster has beaten out rivals from Eli Lilly and Johnson & Johnson as the first interleukin inhibitor approved in China

Source: Fierce Pharma

Mavenclad 

Merck KGaA has finally claimed an FDA approval for its oral multiple sclerosis therapy Mavenclad, eight years after being turned down by the US regulator.

Source: Pharmaphorum

Myrbetriq 

Zydus Cadila has received approval from the US FDA to market Myrbetriq (mirabegron), an extended-release formulation selective beta 3-adrenoceptor agonist.

Source: The Pharma Letter

Asceniv

The US FDA has approved ADMA Biologics’ intravenous immune globulin 10% liquid for the treatment of primary humoral immunodeficiency disease in patients aged over 12 years.

Source: MPR

Go to top

Share this article